Last reviewed · How we verify
Continuous Infusion of ropivacaine
At a glance
| Generic name | Continuous Infusion of ropivacaine |
|---|---|
| Sponsor | Henry Ford Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia (PHASE4)
- Intrapleural Ropivacaine Infusion in Cardiac Surgery (PHASE4)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (PHASE4)
- PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies (NA)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Comparing PIEB and CEI for Labor Pain Relief (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Infusion of ropivacaine CI brief — competitive landscape report
- Continuous Infusion of ropivacaine updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI